$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying - Comtech Telecom ( NASDAQ:CMTL ) , Alvarium Tiedemann Hldgs ( NASDAQ:ALTI )
Although US stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline - Zymeworks BC ( NYSE:ZYME )
SVB Leerink downgraded Zymeworks Inc ZYME to Market Perform with a price target of $8, down from $19 following the recent divestiture of zanidatamab to Jazz Pharmaceuticals plc JAZZ and the unveiling of the company's early stage pipeline.
Zymeworks ( ZYME ) Up on Licensing Deal With Jazz Pharmaceuticals
Zymeworks (ZYME) inks a deal to license its lead candidate, zanidatamab, to Jazz Pharmaceuticals for the development and commercialization of the candidate in all territories except Asia-Pacific.
Zymeworks Inc. ( ZYME ) Surges 15.9%: Is This an Indication of Further Gains?
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Intuitive Surgical, Netflix, ASML And Other Big Gainers From Wednesday - Amprius Technologies ( NYSE:AMPX ) , ASML Holding ( NASDAQ:ASML )
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping 100 points. Here is the list of some big stocks recording gains in the previous session. Amprius Technologies, Inc. AMPX jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million ...
Why Zymeworks Stock Is Soaring Today
Investors applauded a major licensing deal with Jazz Pharmaceuticals.
Why Zymeworks ( ZYME ) Shares Are Trading Higher Premarket Today - Jazz Pharmaceuticals ( NASDAQ:JAZZ ) , Zymeworks ( NYSE:ZYME )
Jazz Pharmaceuticals plc JAZZ will acquire development and commercialization rights to Zymeworks Inc's ZYME zanidatamab across all indications in the U.S., Europe, Japan, and all other territories except for those Asia/Pacific territories that Zymeworks previously licensed to BeiGene Ltd BGNE.
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz's option, and further potential regulatory and commercial milestones for total ...
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday - Abeona Therapeutics ( NASDAQ:ABEO ) , ACM Research ( NASDAQ:ACMR )
Agrify Corporation AGFY climbed 53.8% to close at $1.45. FedNat Holding Company FNHC gained 48% to settle at $0.52. IMARA Inc. IMRA shares climbed 46.9% to close at $3.79 after the company, along with Enliven Therapeutics, announced a merger agreement to combine the two companies in an all-stock ...
Dow Dips 375 Points; S&P 500 Down Over 2% - Imara ( NASDAQ:IMRA ) , First Republic Bank ( NYSE:FRC )
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 375 points on Friday. The Dow traded down 1.25% to 29,662.76 while the NASDAQ fell 2.68% to 10,363.83. The S&P 500 also fell, dropping, 2.10% to 3,592.94. Also check this: Market Volatility Declines Following ...
Nasdaq Tumbles Over 200 Points; Crude Oil Falls Sharply - Imara ( NASDAQ:IMRA ) , First Republic Bank ( NYSE:FRC )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 200 points on Friday. The Dow traded down 0.74% to 29,817.07 while the NASDAQ fell 2.09% to 10,426.14. The S&P 500 also fell, dropping, 1.59% to 3,611.60.
Wells Fargo, JPMorgan, Citigroup And Some Other Big Stocks Moving Higher On Friday - AVEO Pharmaceuticals ( NASDAQ:AVEO ) , ADC Therapeutics ( NYSE:ADCT )
U.S. stocks traded lower, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today's session. Gravitas Education Holdings, Inc. GEHI shares surged 66% to $24.90. Nutanix, Inc.
Uber, Lyft, AZZ And Other Big Losers From Tuesday - Angi ( NASDAQ:ANGI ) , ACM Research ( NASDAQ:ACMR )
U.S. stocks closed mixed with the Nasdaq Composite dropping more than 100 points on Tuesday. Here is the list of some big stocks recording losses in the previous session. AZZ Inc. AZZ shares dipped 22.1% to close at $30.41 after the company reported worse-than-expected Q2 adjusted EPS results.
Denali Therapeutics Inc. ( DNLI ) Moves 17.7% Higher: Will This Strength Last?
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zymeworks ( NYSE:ZYME ) - Zymeworks Highlights Early Data From Zanidatamab Zovodotin Trial In HER2-Positive Tumors
Zymeworks Inc ZYME presented preliminary results from its Phase 1 trial evaluating zanidatamab zovodotin ( ZW49 ) for HER2-positive tumors. The data were presented at the European Society for Medical Oncology Annual Congress.
ZYME: 3 Stocks Downgraded to
While a slight decline in U.S. inflation in July, a robust job market, better-than-expected corporate earnings, and the passage of the Inflation Reduction Act helped revive investors' confidence, concerns over a potential recession, as indicated by the deepening of the yield curve inversion, and ...
Exelixis ( EXEL ) Q2 2022 Earnings Call Transcript
EXEL earnings call for the period ending June 30, 2022.
Zymeworks Inc. ( ZYME ) Reports Q2 Loss, Misses Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -4.30% and 34.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences ( ALIM ) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 26.23% and 8.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay
June 10 ( Reuters ) - Cancer therapy developer Zymeworks Inc ( ZYME.N ) said on Friday it had adopted a "poison pill" to thwart a hostile takeover from All Blue Capital, a month after rejecting the investment firm's $773 million bid on valuation grounds.
Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer
"In the past year, Cytovia has graduated into a fully-integrated global biotech with R&D and cell manufacturing capabilities.
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.
Zymeworks Turns Down All Blue's Hostile Bid
Zymeworks Inc's ( NYSE: ZYME ) board has officially turned down an unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons. The company rejected the buyout at $10.50 per share. All Blue's bid "significantly undervalues its prospects related to the company's
Zymeworks rejects All Blue Capital's $773 million buyout bid
Cancer drug developer Zymeworks rejects All Blue Capital's $773 million bid Reuters
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor All Blue Urges Zymeworks Board to Engage with All Blue on Its Compelling $10.50 Per Share Acquisition Proposal, Consistent with the Board's
Zymeworks Inc. ( ZYME ) Reports Q1 Loss, Lags Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -22.68% and 49.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kezar Life's Lead Asset Fails To Top Placebo In Muscle Inflammation Disease
Kezar Life Sciences Inc ( NASDAQ: KZR ) announced topline results from the PRESIDIO Phase 2 trial of zetomipzomib ( KZR-616
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics ( NASDAQ:MCRB ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
• Obsidian Energy ( AMEX:OBE ) is projected to report quarterly earnings at $0.41 per share on revenue of $156.00 million.
• Internationa
Former AstraZeneca oncology head to help All Blue in Zymeworks takeover bid
May 3 ( Reuters ) - Investment firm All Blue Capital would be advised by Alan Barge, former oncology head at British drugmaker AstraZeneca Plc ( AZN.L ) , in its bid to acquire drug developer Zymeworks Inc ( ZYME.N ) , according to a press statement seen by Reuters.
5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Short sellers could be looking to close out their position and can face a loss if they have to buy bac
Zymeworks Inc. ( ZYME ) Surges 23.2%: Is This an Indication of Further Gains?
Zymeworks Inc. (ZYME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
70 Biggest Movers From Friday
Gainers
GTY Technology Holdings Inc. ( NASDAQ: GTYH ) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners.
Vaxxinity, Inc. ( NASDAQ: VAXX ) jumped 84.2% to close at $6.95. Vaxxinity Executive chairman Lou Reese purchased 22,912 shares at $3.48 per share.
B
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
Vaxxinity ( NASDAQ:VAXX ) stock moved upwards by 45.9% to $5.5 during Friday's regular session. Trading volume for this security as of 13:30 EST is 12.1 million, which is 15165.5% of its average full-day volume over the last 100 days. The company's market cap stands at $692.1 million.
Zyme
48 Stocks Moving In Friday's Mid-Day Session
Gainers
Belite Bio Inc. ADR ( NASDAQ: BLTE ) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS.
GTY Technology Holdings Inc. ( NASDAQ: GTYH ) shares jumped 116.3% to $6.12 as the company agreed to be acquired by GI Partners.
Vaxxinity, Inc. ( NASDAQ: VAXX )
Why Zymeworks Stock Is Rocketing Higher on Friday
New cancer trial results from the clinical-stage biopharmaceutical company inspired a juicy buyout offer.
Mid-Morning Market Update: Markets Down; Nasdaq Falls 100 Points
U.S. stocks traded lower this morning, with the Nasdaq Composite dropping around 100 points on Friday.
Following the market opening Friday, the Dow traded down 0.30% to 33,816.14 while the NASDAQ fell 0.82% to 12,766.29. The S&P also fell, dropping, 0.74% to 4,255.95.
Also check this: Executives Buy
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Bristol Myers' Oral Heart Disease Drug Scores FDA Approval
The FDA has approved Bristol Myers Squibb & Co's ( NYSE: BMY ) Camzyos ( mavacamten ) for obstructive hypertrophic cardiomyopathy ( obstru
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers
Finch Therapeutics Group ( NASDAQ:FNCH ) stock increased by 55.7% to $3.27 during Friday's pre-market session. The company's market cap stands at $155.5 million.
Zymeworks ( NYSE:ZYME ) stock rose 47.78% to $7.33. The company's market cap stands at $423.2 million.
Summit Therapeutics (
28 Stocks Moving in Friday's Pre-Market Session
Gainers
Zymeworks Inc. ( NASDAQ: ZYME ) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per share.
Finch Therapeutics Group, Inc. ( NASDAQ: FNCH ) shares rose 40% to $2.94 in pre-market trading. The U.S. Fo
EXCLUSIVE All Blue Capital in $773 mln bid for Zymeworks-sources
April 28 ( Reuters ) - Investment firm All Blue Capital has approached Zymeworks Inc ( ZYME.N ) , a developer of antibody therapies for cancer, with a $773 million acquisition offer, people familiar with the matter said on Thursday.
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
Areas of Significance In Today's 52-Week Lows:
JPMorgan Chase ( NYSE:JPM ) was the largest company by market cap to set a new 52-week low.
Reshape Lifesciences ( NASDAQ:RSLS ) was the smallest company by market cap to set a new 52-week low.
Sio G
Zymeworks Inc. ( ZYME ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms ( NASDAQ:FB ) was the biggest company on a market cap basis to set a new 52-week low.
The smallest company by market cap to set a new 52-week low was AnPac Bio-Medical Science ( NASDAQ
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows.
Intriguing Points From Today's 52-Week Lows:
Salesforce ( NYSE:CRM ) was the largest firm by market cap to set a new 52-week low.
Vallon Pharmaceuticals ( NASDAQ:VLON ) was the smallest firm by market cap to set a new 52-week low.
Ampio Pharmaceut
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows.
Noteworthy Mentions In Today's 52-Week Lows:
The largest company in terms of market cap to set a new 52-week low was Sony Group ( NYSE:SONY ) .
Nova Lifestyle ( NASDAQ:NVFY ) was the smallest firm by market cap to set a new 52-week low.
Cassava Scie
Stocks That Hit 52-Week Lows On Monday
On Monday, 466 companies hit new 52-week lows.
Noteworthy Highlights From Today's 52-Week Lows:
The largest company by market cap to set a new 52-week low was Walt Disney ( NYSE:DIS ) .
The smallest company on a market cap basis to set a new 52-week low was InVivo Therapeutics Hldg ( NASDAQ:NVIV )
HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks
Atreca Inc ( NASDAQ: BCEL ) announced a licensing agreement with Zymeworks Inc ( NYSE: ZYME ) to utilize their ZymeLink technology to develop novel antibody-drug conjugates ( ADCs ) .
The agreement includes a two-year research term for Atreca to evaluate antibodies as ADCs using ZymeLink with t
Atreca Announces Expansion of Preclinical Pipeline
Atreca Announces Licensing Agreement with Zymeworks
Atreca Declares EphA2-Targeting ADC ( ATRC-301 ) as Clinical Candidate
Virtual R&D Day scheduled for today at 4:15 p.m. EDT
SAN CARLOS, Calif., April 05, 2022 ( GLOBE NEWSWIRE ) -- Atreca, Inc. ( Atreca ) ( NASDAQ:BCEL ) , a clinical-stage
